Replimune appoints Veleka Peeples-Dyer to Board of Directors, effective June 1, 2023

Replimune Group, Inc.

Veleka Peeples-Dyer appointed to Board as tenth member, filling vacancy from Board size increase.
She also joins the Audit Committee, replacing Dieter Weinand; receives annual retainers of $45,000 (Board) and $10,000 (Audit).
Granted nonqualified stock option for 50,400 shares at $18.48 strike, vesting 25% after one year then monthly over 24 months.
Ms. Peeples-Dyer brings over 24 years of life sciences legal and compliance experience, including executive roles at biopharma companies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Veleka Peeples-Dyer

Director

REPL · Replimune Group, Inc.

Effective: 2023-06-01
Filed: June 5, 2023, 7:59 PM ET

On June 1, 2023, based on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Replimune Group, Inc. (the "Company"), the Board appointed Veleka Peeples-Dyer to serve as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Veleka Peeples-Dyer was appointed as Director at Replimune Group, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 1, 2023, based on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Replimune Group, Inc. (the "Company"), the Board appointed Veleka Peeples-Dyer to serve as a member of the Board, effective immediately.

View on SEC.gov

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-067856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.